Jump to Navigation

Facebook Connect

User login

NLA Meetings

Meeting Info

 

Top five reasons to attend the Fall CLU:

Featured Presentations

 

  1. Attend stimulating debates from world-renowned thought leaders on controversial topics in lipidology: HDL-C, dietary cholesterol, and goal setting
  2. Learn how to implement the NLA Recommendations into your patient care regimens
  3. Hear about the latest pharmacologic interventions
  4. Earn up to 12.75 CME/CE credits
  5. Immerse yourself in one of the two pre-conference workshops, and earn even more CME/CE
 

Click here to download Fall CLU Program

Friday, September 18, 2015

Session I -On the Cutting Edge: New Pharmacologic Vistas in Clinical Lipidology

3:40 - 3:50 PM Chapter Presidents Welcome & Introduction
3:50 - 4:00 PM ARS Questions for Session I
4:00 - 4:30 PM Pharmacologic Marked LDL-C Reduction ―Potential Benefits and Safety Concerns Peter W.F. Wilson, MD, FNLA
4:30 - 5:00 PM Update on PCSK9 Inhibition―How Will Approval Change Clinical Lipidology? James M. McKenney, PharmD, CLS, FNLA
5:00 - 5:30 PM ATP Citrate Lyase Inhibition―A New Mechanism for LDL-C Reduction Christie M. Ballantyne, MD, FNLA
5:30 - 6:00 PM ARS Questions and Q&A Panel
6:00 - 7:00 PM Welcome Reception in Exhibit Hall
Saturday, September 19, 2015
7:00 - 7:50 AM Breakfast in Exhibit Hall
7:50 - 8:00 AM Housekeeping Notes & ARS Questions for Session II

Session II ― Clinical Lipidology in 2015: Who We Are and What We Need to Know

8:00 - 8:30 AM Clinical Lipidology: A Subspecialty Whose Time Has Come Carl E. Orringer, MD, FNLA*
8:30 - 9:00 AM Key Articles in Clinical Lipidology in 2015 Harold E. Bays, MD, FNLA*
9:00 - 9:30 AM Key Ongoing Research Studies in Clinical Lipidology Sergio Fazio, MD
9:30 - 10:00 ARS Questions and Q&A Panel
10:00 - 10:20 AM Break in Exhibit Hall

Session III ― Controversies in Clinical Lipidology

10:20 - 10:30 AM ARS Questions for Session III
Debate: HDL―Controversies and New Directions
10:30 - 10:40 AM HDL has been an elusive target; the focus should be on atherogenic lipoproteins and proven therapies Benjamin J. Ansell, MD, FNLA*
10:40 - 10:50 AM HDL Therapeutics: The Start of a New Era Robert S. Rosenson, MD*
10:50 - 11:00 AM Rebuttal
Debate: Are Lipoprotein Goals and Monitoring Necessary?
11:00 - 11:10 AM Lipoprotein Goals and Monitoring are Not Necessary Patrick E. McBride, MD, MPH
11:10 - 11:20 AM Lipoprotein Goals and Monitoring are of Value in Patient Care W. Virgil Brown, MD, FNLA*
11:20 - 11:30 AM Rebuttal
Debate: Is Restriction of Dietary Cholesterol Necessary for CVD Prevention?
11:30 - 11:40 AM Dietary Cholesterol Restriction: Much Hype about Nothing Alice Lichtenstein, D.Sc.
11:40 - 11:50 AM Dietary Cholesterol Restriction is Still Important Penny M. Kris- Etherton, PhD, RD, CLS, FNLA
11:50 - 12:00 PM Rebuttal
12:00 - 12:30 PM ARS Questions and Q&A Panel
12:30 - 12:45 PM NLA News & Notes
12:45 - 1:45 PM Lunch in Exhibit Hall

Session IV ― Lipid Management in Special Populations: Focus on the NLA Recommendations, Part 2

1:45 - 1:55 PM ARS Questions for Session IV
1:55 - 2:25 PM Overview of the NLA Recommendations, Part 2 Kevin C. Maki, PhD, CLS, FNLA
2:25 - 2:55 PM Management of Dyslipidemia in Women― What is the Evidence? Pamela B. Morris, MD, FNLA*
2:55 - 3:25 PM Management of the Patient with Progressive Atherosclerosis Despite Evidence-Based Therapy Peter H. Jones, MD, FNLA*
3:25 - 3:55 PM ARS Questions and Q&A Panel
3:55 - 4:05 PM Break

Session V ― Managing Barriers to ASCVD Risk Reduction

4:05 - 4:15 PM ARS Questions for Session V
4:15 - 4:45 PM Statin Intolerance as a Barrier to Risk Reduction Paul D. Thompson, MD
4:45 - 5:15 PM How Effective is Dietary Therapy for Marked Hypertriglyceridemia? Katherine S. Rhodes, PhD, RD
5:15 - 5:45 PM The Evolving Role of Lp(a) in Clinical Lipidology Alan T. Remaley, MD, PhD
5:45 - 6:15 PM ARS Questions and Q&A Panel
Foundation of the NLA Event
6:30 PM
Sunday, September 20, 2015

Session VI ― The Impact of Weight Reduction on Lipid Metabolism and Lipid Levels

7:50 - 8:00 AM Housekeeping Notes & ARS Questions for Session VI
8:00 - 8:30 AM What Is the Effect of Changes in Body Fat on Dyslipidemia? Eric Westman, MD, MHS
8:30 - 9:00 AM What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel H. Bessesen, MD
9:00 - 9:30 AM What Are the Effects of Bariatric Surgery on Lipid Metabolism and Lipid Levels? Harold E. Bays, MD, FNLA*
9:30 - 10:00 AM ARS Questions and Q&A Panel
10:00 AM Adjourn

Upon completion of the educational activity, participants should be able to:

Educational Objectives

At the conclusion of this activity, registered nurses and nurse practitioners should be able to provide appropriate counsel for patients and their families.

At the conclusion of this activity, all participants should be able to:

Session I: On the Cutting Edge: New Pharmacologic Vistas in Clinical Lipidology

  • Describe the efficacy, safety, and mechanisms of LDL Pharmacotherapies
  • Identify emerging therapies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce CVD risk in patient populations with severely elevated LDL-C levels
  • Describe the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipoprotein metabolism
  • Identify the potential roles that novel LDL-targeting therapies may play in reducing risk in patients with CVD

Session II: Clinical Lipidology: Who We Are, What We Need to Know and How We Communicate

  • Define strategies and educational approaches used to advance the recognition of clinical lipidology as a subspecialty of medicine
  • Review current literature of particular importance to the practice and science of clinical lipidology
  • Describe the efficacy, safety, and mechanisms of action of novel lipid-targeted pharmacotherapies

Session III: Controversies in Clinical Lipidology

  • Examine the results of recent HDL-C-related research and their clinical implications on patient management
  • List the available and potential laboratory and clinical measures of HDL functionality
  • Outline current patient guidelines for the diagnosis, management and treatment of dyslipidemia
  • Apply guidelines into daily practice to help patients reach goals
  • Interpret evidence from recent literature on dietary cholesterol
  • Examine evidence around Current Dietary Recommendations for Heart Health
  • Apply new strategies for implementing dietary recommendations for lipid management

Session IV: Lipid Management in Special Populations: Focus on the NLA Recommendations Part II

  • Incorporate appropriate treatment strategies for special risk populations, including minorities, women and children
  • Describe the identification and treatment  of residual risk in patients with cardiovascular disease (CVD)

Session V: Managing Barriers to ASCVD Risk Reduction

  • Review the mechanism of statin-drug interactions including the impact on statin induced muscle side effects
  • Assess the impact of diet & weight reduction on management of hypertriglyceridemia
  • Evaluate the application and limitations of novel biomarkers [LP(a)] for CV risk detection

Session VI: The Impact of Weight Reduction on Lipid Metabolism and Lipid Levels

  • Recognize the relationship between obesity and diabetes and discuss the role of inflammation in dyslipidemia
  • Review the approved pharmacologic therapies for the treatment of obesity including their impacts on lipid metabolism
  • Identify the pros and cons of bariatric surgery for the treatment of obesity

CME credit provided by the National Lipid Association

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Lipid Association designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

American Academy of Family Physicians
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

CE credit provided by Postgraduate Institute for Medicine

Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Session I- Universal Activity Number 0809-9999-15-212-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session II- Universal Activity Number 0809-9999-15-213-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Session III – Universal Activity Number 0809-9999-15-214-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session IV– Universal Activity Number 0809-9999-15-215-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session V – Universal Activity Number 0809-9999-15-216-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Session VI – Universal Activity Number 0809-9999-15-217-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
This educational activity for 12.5 contact hours is provided by the Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Session I- 2.1 credits; Session II- 2.0 credits; Session III- 2.1 credits; Session IV- 2.1 credits; Session V- 2.1 credits; Session VI- 2.1 credits.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Benjamin J. Ansell, MD, FNLA

Professor of Medicine Cardiology
UCLA
School of Medicine
Co-Director UCLA CHAMP Program
Los Angeles, CA
Diplomate, American Board of Clinical Lipidology

Christie M. Ballantyne, MD, FNLA

Professor of Medicine
Chief, Section of Cardiovascular Research
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Harold E. Bays, MD, FNLA

Medical Director/President
Louisville Metabolic and Atherosclerotic
Research Center
Louisville, KY
Diplomate, American Board of Clinical Lipidology

Daniel H. Bessesen, MD

Associate Director
Anschutz Health and Wellness Center
Professor, Endocrinology, Metabolism and Diabetes
University of Colorado
Associate Director
Colorado Nutrition Obesity Research Center (NORC)
Denver, CO

W. Virgil Brown, MD, FNLA

Charles Howard Candler Professor Emeritus
Emory University School of Medicine
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

Sergio Fazio, MD, PhD, FNLA

William & Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology

Peter H. Jones, MD, FNLA

Associate Professor
Department of Medicine
Baylor College of Medicine
Houston, TX
Diplomate, American Board of Clinical Lipidology

Penny Kris-Etherton, PhD, RD, FNLA

Distinguished Professor of Nutrition
The Pennsylvania State University
University Park, PA

 

Alice H. Lichtenstein, DSc

Gershoff Professor of Nutrition Science and Policy
Director and Senior Scientist, Cardiovascular Nutrition Laboratory
Tufts University
JM USDA Human Nutrition Research Center on Aging
Boston, MA

Kevin C. Maki, PhD, FNLA

Chief Science Officer
Midwest Center for Metabolic & Cardiovascular Research
Chicago, IL

Patrick E. McBride, MD, MPH

Professor of Medicine & Family Medicine
Co-Director Preventive Cardiology
Associate Dean
University of Wisconsin
Madison, WI
Diplomate, American Board of Clinical Lipidology

James M. McKenney, PharmD, FNLA

CEO, National Clinical Research, Inc.
Manakin Sabot, VA

 

Pamela B. Morris, MD, FNLA

Director, Preventive Cardiology
Co-Director, Women’s Heart Care
Medical University of South Carolina
Charleston, SC

Carl E. Orringer, MD, FACC, FNLA

President-Elect, National Lipid Association
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL
Diplomate, American Board of Clinical Lipidology

Alan T. Remaley, MD, PhD

Section Chief of Lipoprotein Metabolism Section Cardiopulmonary Branch
National Heart Lung, and Blood Institute
Bethesda, MD

Katherine S. Rhodes, PhD, RD,

Cardiovascular Dietitian
Division of Cardiovascular Medicine
Preventive Cardiology
University of Michigan Health System
Ann Arbor, MI

Robert S. Rosenson, MD

Director
Cardiometabolic Disorders
Mount Sinai Heart
Professor of Medicine (Cardiology)
Icahn School of Medicine
Mount Sinai
New York, NY
Diplomate, American Board of Clinical Lipidology

Paul D. Thompson, MD

Chief of Cardiology
Hartford Hospital
Hartford, CT

Eric C. Westman, MD, MHS

Associate Professor of Medicine
Duke University Health System
Director, Duke Lifestyle Medicine Clinic
Durham, NC,

Peter W. F. Wilson, MD, FNLA

Professor of Medicine, Division of Cardiology
Emory University School of Medicine
Professor of Public Health
Rollins School of Public Health
Director, Epidemiology and Genomic Medicine
Atlanta VA Medical Center
Atlanta, GA
Diplomate, American Board of Clinical Lipidology

 

Register for the 2015 Fall Clinical Lipid Update

Must be logged in to see NLA member price

Personal Information

Contact Information

Which meetings or courses would you like to attend?

NLA Member Discount Rate up to 2015-08-07NLA Member Discount Rate after 2015-08-07Non-Member RateTrainee Rate*
*Non-Member Trainees must register with .PDF form.
Clinical Lipid Update
September 18-20, 2015
Includes one admission badge to Exhibit Hall for all food functions.
$495.00 $545.00 $895.00 $75.00
Masters in Lipidology Course
September 17-18, 2015
$750.00 $750.00 $1250.00 $395.00
NLA Lipid Academy
September 17-18, 2015
$550.00 $550.00 $950.00 $0.00
Foundation Event- Cooking with the Foundation 80 x
Guest Pass- Exhibit Hall 150 x

Total

$0.00

Payment Information

Exhibitors

Plan now for your company to participate in the National Lipid Association’s Clinical Updates in 2015. Our meeting provides you with a unique opportunity to reach our target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians and Allied Health Professionals involved in dyslipidemia management, as well as our distinguished board and faculty.

Our numerous sponsorship opportunities allow you to connect with our members in a whole new way, providing you with maximum return on your investment. The exhibit hall provides a unique setting for you and your company’s representatives to interact daily with attendees as they study the latest advances in their professions.

 

Amarin Pharma Inc.
Amarin Pharma Inc. is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's first FDA approved product is available in the United States by prescription.
www.amarincorp.com

Amgen Inc.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com

AstraZeneca LP
AstraZeneca is focused on the discovery, development and commercialization of medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, and neuroscience diseases.
www.astrazeneca.com

Endurance Products Co.
Endurance Products Company (EPC), manufactures and markets Endur-acin®, the clinically proven wax-matrix extended release niacin since 1976. RCTs of Endur-acin® have consistently demonstrated an unsurpassed in tolerability with dropout rates averaging 4.5%. Clinical samples of are available.
www.endur.com

Genzyme, a Sanofi Company
Genzyme discovers and delivers transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Visit www.genzyme.com.

Kaneka Pharma America, LLC
Kaneka’s Liposorber Apheresis System is FDA approved for the acute reduction of LDL cholesterol (70-80%) in patients with Familial Hypercholesterolemia and patients who cannot meet their LDL-C goals despite maximum drug therapy. The Liposorber treatment is reimbursed by government and private insurance, and is used in hospitals, clinics, and physician offices across the country.
www.liposorber.com

Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc. is focused in the area of cardiometabolic diseases and focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products, and business development activities. For more information about Kowa Pharmaceuticals America, visit www.kowapharma.com.

Lilly
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission. To learn more, visit www.lilly.com.

Quest Diagnostics
Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health. Visit 4myheart.com and QuestDiagnostics.com.

Synageva BioPharma Corp.
Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of products for patients with rare diseases. Our pipeline programs include the lead program, Kanuma™ (sebelipase alfa) for lysosomal acid lipase deficiency (LAL D), SBC-103 for mucopolysaccharidosis IIIB (MPS IIIB), and SBC-105 for generalized arterial calcification of infancy (GACI) and other rare calcification diseases.
www.synageva.com

Cooking with the Foundation

Support the Foundation of the National Lipid Association by attending a fun and interactive cooking class at the Pittsburgh’s Crate Cooking School. Join your friends and colleagues for a brief reception followed by an interactive cooking demonstration by a seasoned chef. Then sit, relax, and enjoy the finished delicious and nutritious meal with wine.

Saturday, September 19

1960 Greentree Rd. | Pittsburgh, PA 15220

6:45–9:15 pm

$80/person

Meet in the lobby of the Omni William Penn Hotel at

6:30 pm for a quick bus ride to the venue.

Omni William Penn Hotel

Omni William Penn Hotel
530 William Penn Place
Pittsburgh, PA

 
For reservations, please call 1-800-843-6664  and ask for the 2015 NLA Clinical Lipid Update Fall Meeting's room rate. A special room rate starting at $169 per night plus tax has been arranged. This group rate will be available until August 26, 2015, or until the room block is filled. Please make your reservation early as we do anticipate the room block will sell out.
 

To learn more about the hotel, please visit omnihotels.com/Pittsburgh‎

Coming Soon...

0
No votes yet

Coming soon.

2015 SATELLITE SYMPOSIA GUIDELINES

The National Lipid Association (NLA) has established that independently developed and CME/CE certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members. In this regard, we are pleased to offer satellite symposia slots in conjunction with our 2015 Clinical Lipid Updates.

Satellite symposia address educational needs and performance gaps that complement the NLA scientific program agenda. They may include one or a number of speakers and may cover one or several topics addressing the educational gaps of lipid specialists.

The following deadlines and guidelines provide important information about holding a Satellite Symposium at the 2015 Clinical Lipid Updates and the process for completing a symposium proposal. Please contact the NLA business development department directly (contact below) should there be any questions or further information required. See you in 2015!

DOWNLOAD 2015 SATELLITE SYMPOSIA GUIDELINES 2015

Contact:
Amina Resheidat
Program Coordinator
904-309-6212

aresheidat@lipid.org

0
No votes yet

This form is for submitting questions you may expect to have for presenters on the various topics offered through out the NLA's 2015 Annual Scientific Session. Please provide your name, select the talk for which your questions applies and provide a brief synopsis of your question. For reasons of time, we cannot guarantee that every speaker will be able to answer every question submitted.



by Dr. Radut.